| Literature DB >> 28511707 |
Constanze Bening1, Khaled Hamouda2, Mehmet Oezkur2,3, Christoph Schimmer2, Ina Schade2, Armin Gorski2, Ivan Aleksic2, Rainer Leyh2.
Abstract
BACKGROUND: There is growing evidence from the literature that right anterior minithoracotomy aortic valve replacement (RAT-AVR) improves clinical outcome. However, increased cross clamp time is the strongest argument for surgeons not performing RAT-AVR. Rapid deployment aortic valve systems have the potential to decrease cross-clamp time and ease this procedure. We assessed clinical outcome of rapid deployment and conventional valves through RAT.Entities:
Keywords: Aortic valve replacement; Heart valve prosthesis biological rapid deployment aortic valve; Minimally invasive surgery
Mesh:
Year: 2017 PMID: 28511707 PMCID: PMC5434633 DOI: 10.1186/s13019-017-0598-0
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Patient’s characteristic
| Variable | All pts.( | C-Group-( | R-Group( |
|
|---|---|---|---|---|
| Age (y) | 75.9 (SD 5.7) | 74.2 (SD 6.6) | 74.1 (SD 6.6) | 0.058 |
| BSA (m2) | 1.89 (SD 0.17) | 1.93 (SD 0.13) | 1.86 (SD 0.18) | 0.11 |
| Female gender; n (%) | 24 (35.3) | 8 (32.0) | 16 (37.7) | >0.5 |
| COPD; n (%) | 7 (10.3) | 2 (8) | 5 (11.6) | >0.5 |
| DM; n (%) | 26 (38.2) | 5 (20) | 21 (48.8) | 0.022 |
| Creatinine (mg/dl) | 1.10 (0.86–1.4) | 1.01 (0.7–1.5) | 1.20 (1.0–1.4) | 0.31 |
| CKD-EPI (ml/min/1,73 m2) | 64.5 (SD 21.2) | 69.8 (SD 27.0) | 61.5 (SD 16.5) | 0.18 |
| Chronic AF; n (%) | 15 (22.1) | 7 (28) | 8 (18.6) | 0.38 |
| PAVD; n (%) | 9 (13.2) | 3 (12) | 6 (14) | >0.5 |
| Stroke; n (%) | 4(5.9) | 2(8.0) | 2(4.7) | >0.5 |
| Art.hypertension; n(%) | 63(94) | 21(87.5) | 42(97.7) | 0.13 |
| Pul. hypertension; n (%) | 24(35.3) | 7(28.0) | 17(39.5) | 0.43 |
| NYHA class III -IV; n (%) | 40 (58.8) | 14 (56) | 26 (60.5) | >0.5 |
| LVEF (%) | 54 (SD 12.8) | 54.2 (SD 14.0) | 53.9 (SD 12) | 0.25 |
| EuroSCORE II (%) | 5.3 (3.7–8.9) | 5.0 (3.1–9.1) | 5.7 (3.9–9.0) | 0.29 |
| Preoperative EOA, cm2 | 0.78 (SD 0.22) | 0.75 (SD 0.25) | 0.79 (SD 0.19) | >0.5 |
| Preoperative mean aortic valve gradient, mmHG | 49.6 (SD 11.6) | 48.8 (SD 12.7) | 50.1 (SD 10.9) | >0.5 |
Data presented as mean ± standard deviation (SD), median and IQR, or number of observations (n) with proportions (%)
BSA body surface area, COPD Chronic obstructive pulmonary disease, DM diabetes mellitus, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, AF atrial fibrillation, NYHA New York Heart Association Classification, LVEF left ventricular ejection fraction, PAVD peripheral arterial vascular disease; pulmonary hypertension: mean pulmonary pressure > 30 mmHG; EOA effective orifice area
Intraoperative characteristics
| Variable | All pts.( | C-Group-( | R-Group( |
|
|---|---|---|---|---|
| OP-time, min. | 182 (167–207) | 189 (169–219) | 180 (152–197) | 0.071 |
| CPB-time, min. | 90 (SD 36.4) | 106.6 (SD 23.2) | 80.4 (SD 39.3) | 0.001 |
| X-clamp time, min. | 51.7 (SD 20.2) | 68.3 (SD 20.3) | 42.1 (SD 12.6) | <0.001 |
| Conversion, n(%) | 2 (2.9) | 0 (0) | 2 (4.6) | >0.5 |
| Valve Diameter, mm | 23 (21–25) | 25 (23–27) | 23 (21–25) | 0.009 |
Data presented as mean ± standard deviation (SD), median and IQR, or number of observations (n) with proportions (%)
OP operation, CPB cardiopulmonary bypass
x-clamp, aortic cross clamp
Postoperative characteristics
| Variable | All pts.( | C-Group-( | R-Group( |
|
|---|---|---|---|---|
| Assisted ventilation (h) | 11 (8–15) | 12 (10–17) | 11 (8–14) | 0.14 |
| Reoperation, n(%) | 0 (0) | 0 (0) | 0 (0) | >0.5 |
| Transfusion, n(%) | 38 (57.4) | 12 (48.0) | 26 (60.5) | >0.5 |
| RBC, units | 0 (0–2) | 0 (0–2) | 0 (0–2) | >0.5 |
| New–AF, n (%) | 6 (8.8) | 3 (12) | 3 (7) | >0.5 |
| Temp. AVB III°,n(%) | 3 (4.4) | 0 (0) | 3 (7.0) | 0.29 |
| Perm. AVB III°,n(%) | 1 (1.5) | 0 (0) | 1 (2.3) | >0.5 |
| TND, n(%) | 1(1.5) | 1(4.0) | 0 (0) | 0.37 |
| ICU stay, (d) | 1(1–3) | 1(1–3) | 1(1–3) | >0.5 |
| 30d mortality, n(%) | 2(2.9) | 0(0) | 2 (4.7) | >0.5 |
Data presented as mean ± standard deviation (SD), median and interquartile range (IQR), or number of observations (n) with proportions (%)
RBC red blood cell, New-AF new onset atrial fibrillation, Temp AVB III°, temporary atrioventricular block third degree; perm. AVB III° permanent atrioventricular block third degree, TND temporary neurological dysfunction, ICU intensive care unit